Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus caused by an accumulation of eosinophils, which leads to difficulty in swallowing food and the potential for dangerous food impaction. Topical steroids and proton pump inhibitors are the mainstays of clinical management for EoE; however, the indication has no FDA-approved therapy. EoE has an active pipeline; Takeda’s budesonide oral suspension is under FDA priority review, and both Sanofi / Regeneron’s Dupixent and AstraZeneca’s Fasenra are in Phase III development. As the EoE treatment landscape evolves, this report offers insights from real-world claims data into prescribing trends in EoE to help developers better understand current treatment practices and to help define the market niche for their emerging product.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
Markets covered: United States
Key companies: Various
Key drugs: Omeprazole, Pantoprazole, Fluticasone Propionate, Montelukast, Prednisone, Prednisolone, Lansoprazole, Budesonide, Ranitidine